Cost-Effectiveness of Hypothetical New Cancer Drugs in Patients with Advanced Small-Cell Lung Cancer: Results of a Markov Chain Model by Uyl-de Groot, Carin A et al.
Therapeutics and Clinical Risk Management 2006:2(3) 317–323
© 2006 Dove Medical Press Limited. All rights reserved
317
ORIGINAL RESEARCH
Background: In the last decade, a number of new treatment modalities have been developed
for patients with small cell lung cancer (SCLC). The clinical effects are encouraging, but
little is known about the costs and cost-effectiveness of new drugs.
Methods: A Markov chain model has been developed to project patient outcomes and costs
for patients with advanced SCLC. All patients in the control group were treated with etoposide–
cisplatin chemotherapy. Patients in the study group received a hypothetical new drug. The
model consisted of four states: response, stable disease, progressive disease, and death.
Estimates of transition probabilities were calculated using published data on survival and
recurrence-free survival. For the cost analysis and utility calculation, published data and
expert opinion were used as sources. The duration of the follow-up was maximal 2 years.
Results: The total treatment costs in the etoposide–cisplatin group amounted to €16 038 and
in the alternative treatment groups between €16 644 and €18 171. The number of life years
and quality adjusted life years (QALYs) gained were very small, around 16 days. The cost-
effectiveness ratio varied between €22 208 and €81 443 and the cost–utility ratio varied
accordingly. Results of the sensitivity analysis showed that the results were robust in favor of
etoposide–cisplatin treatment.
Conclusion: SCLC is an illness with a poor prognosis which needed substantial healthcare
resources to optimise patient survival and overall quality of life. New treatment modalities
with better outcome and favourable cost-effective profiles can hopefully be developed.
Keywords: small cell lung cancer, costs, cost-effectiveness, modeling
Introduction
Lung cancer is the leading cause of cancer death in many countries. It is one of the
most lethal malignancies and its incidence is increasing worldwide (ASCO 1997;
Greenlee et al 2000; Banerjee et al 2002). Small-cell lung cancer (SCLC) accounts
for approximately 20%–25% of newly diagnosed cases (Carney 1996; Oliver et al
2001). Often the symptoms of lung cancer are not obvious until the disease is at an
advanced stage and most patients have locally advanced or metastatic disease at the
time of diagnosis (Demetri et al 1996). Over the last few years, a number of new
chemotherapeutic agents have been developed for the treatment of SCLC. These so
called third generation agents have shown increased survival and improved response
rate compared to older regimens. Furthermore, these new agent may play an important
role in palliating symptoms and maintaining quality of life.
The costs associated with the treatment of patients with SCLC can be significant.
However, the only European cost study did not include treatment of SCLC, but
diagnostic methods and hematopoietic growth factors (Oliver et al 2001). Thus, while
the improved clinical effects are encouraging, little is known about the cost and cost-
effectiveness of new drugs. In this article, we examine the cost-effectiveness of
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etoposide plus cisplatin and compare it with an alternative
hypothetical new drug. The question is how effective should
this new drug be and at what cost to be considered cost-
effective.
Design and methods
Patients
The studies reviewed consisted of patients with extensive
SCLC confirmed by histology. Extensive disease is defined
as a disease beyond one hemi-thorax, including
medianastinal lymph nodes and/or supraclavicular lymph
nodes. Other eligibility consisted of, among others, no
previous chemotherapy or radiation therapy, no history or
prior malignant disease, a World Health Organization
(WHO) performance status ≤2, uncontrolled severe heart
disease, and several blood values (among others;
neutrophils, platelets, creatinine) (For details, see: Carney
1996; ASCO 1997; Pujol et al 2001; Banerjee et al 2002).
Markov chain analysis
A Markov chain model has been developed, which projects
patient outcomes and costs of treatment for patients with
advanced SCLC. The model has four states, namely
‘Response’ (R), ‘Stable disease’ (SD), ‘Progressive disease’
(PD), and ‘Death’ (D). Tumor response was defined
according to the WHO recommendations (WHO 1979). A
complete response was defined as the complete
disappearance of all lesions with a negative histology or
repeat fiberoptic bronchoscopy biopsies. A partial response
was defined as equal to or greater than a 50% reduction in
the product of the two longest perpendicular diameters of
the indication lesions. Response, ie, both partial and
complete responses, must have lasted a minimum of 4 weeks
to be confirmed. ‘SD’ was defined as a less than 50%
reduction or a less than 25% increase in this product. ‘PD’
was defined as equal to or greater than a 25% increase in
this product or the appearance of new lesions (Pujol et al
2001). Patients may move from their one state to another,
provided that transition is permitted (see Figure 1).
All patients were initially assumed to be in the state ‘SD’.
Estimates of overall survival and survival to progressive
disease were derived from Kaplan-Meier curves for these
endpoints presented in the literature. Additional assumptions
needed to be made for the probabilities of these events from
within the states ‘R’, ‘SD’, and ‘PD’, based on the opinions
of clinical experts. We assumed that the probability of death
in the ‘PD’ state was 8 times that of ‘SD’ patients. We
assumed the probability of transition to progressive was 4
times more likely if the patient was in ‘SD’ than in ‘R’. The
magnitude of the probability of ‘R’ was calculated so as to
give approximately the same number of responders as was
found in the literature. The probability of remaining in the
state ‘R’ was calculated so that the median time spent in
that state was equal to that found in the literature. Treatment
was assumed to be given only to patients in ‘SD’ or response
and was given for a maximum of 6 cycles. ‘R’ was assumed
to occur only in the first 3 cycles.
All patients received at least two treatment cycles.
Thereafter they may move to any other state. Patients who
move to ‘R’ and who leave that state are assumed to have
entered the state ‘PD’ or to have died. Patients in ‘PD’ either
remain in that state or die. ‘D’ is an absorbing state.
Transition probabilities are assumed to depend on the disease
state, but not on other factors such as age and sex. Each
state had an associated cost (which is also time dependent),
which is used in the cost and cost-effectiveness calculations.
As a result, patients randomly progressed through a series
of states until death or the time of maximum follow-up.
During this progress, the patient accrued costs due to
treatment. Transitions are assumed to occur at the end of
each cycle, which was assumed to be of 4 weeks in length.
The patients are followed for a maximum of 2 years.
Patients received chemotherapy only while they
remained in the states R or SD. Chemotherapy, consisting
of etoposide and cisplatin, was given for a maximum of 6
cycles. During each 28-day treatment cycle, etoposide was
administered on days 1, 2, and 3 at a dose of 100 mg/m
2
followed by a one-week rest period. Cisplatin was
administered on day 2 of each course at a dose of 100 mg/
m
2. Based on expert opinion, a transition to response was
only possible in the first three cycles. ‘PD’ patients will get
Response 
Stable 
disease
Progressive 
disease
Death 
Figure 1 Structure of the Markov model.Therapeutics and Clinical Risk Management 2006:2(3) 319
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best supportive care. Patients, who die, got terminal care.
The effects of second-line treatment were not taken into
account.
Estimates of the transition probabilities were calculated
using published data on survival and recurrence-free
survival (Carney 1996; ASCO 1997; Pujol et al 2001;
Banerjee et al 2002). All estimates were reviewed by two
experts.
Modeling the effect of a new drug
In this analysis, we considered a number of scenarios.
We assumed that the hypothetical new drug was both
clinically more effective than current treatments and more
expensive than etoposide–cisplatin. More specifically, we
assumed that the new treatment increased the probability
of achieving a response, with a subsequent decrease in
moving to ‘SD’ or ‘PD’. On the cost side, we took into
account a small rise and a fairly significant rise in the
cost of chemotherapy.
Costs
The societal perspective was taken. The study focused on
direct medical costs. Considering the severity of the disease
and the typically advanced age of patients at diagnosis, the
indirect costs, ie, costs due to lost productivity, would be
slight and therefore not be included.
For the cost analysis, the micro-costing approach
proposed by Gold et al (1996) has been used. Estimates
of the associated costs are based on resource use and on
Dutch unit prices or Dutch tariffs (Oostenbrink et al
2000). Unit prices are based on previous studies
performed at our institute and specific cost studies are
performed for the most relevant items of resource use.
Tariffs derived from the ‘Farmacotherapeutisch Kompas’
are used for medication and prices for general tests such
a laboratory testing, x-rays, CT-scans etc. are derived
from the ‘Diagnostisch Kompas’ (van Leusden 2000; van
der Kuy 2002). For our analyses 2002 prices and tariffs
are used. Costs are expressed in Euros (€1 ≈ US$1.03).
Table 1 shows an overview of the most important unit
prices.
Using data from the literature, we estimated the cost of
one treatment cycle, including treatment of toxicity, to be
€1391.20 (€1 ≈ $US1.03). Table 2 gives a breakdown of
the costs. We estimated the cost of follow-up of patients in
response or in stable disease to be €101.62, the cost of
follow-up of patients in ‘PD’ state to be €684.37, and the
cost of a subsequent cycle in which death occurred, ie, the
terminal costs, to be €7450 (Smeenk et al 1998).
Utilities
In calculating life years and quality adjusted life years
(QALYs), we used utilities derived from an overview study
in patients with lung cancer and expert opinion (Oliver et al
2001). The utility scores assigned to each state were 0.85
(‘R’), 0.7 (‘SD’), 0.55 (‘PD’), and 0 (‘D’).
For each cycle in the model, the following quantities
were calculated: cumulative cost, patients’ survival per state,
the incremental cost-effectiveness (CE) ratio and cost-
effectiveness adjusted for quality of life (ie, cost-utility
[CU]).
Table 1 Most important cost items
Cost items Unit prices (€ as of 2002)
Hospital day 297.36
Day care 135.00
Outpatient visit 61.32
Etoposide–cisplatin 303.94
Ondansetron 8 mg intravenous 28.54
Ondansetron 8 mg oral 9.04
Hematology tests 8.46
Biochemistry tests 14.10
X thorax 43.92
CT thorax 211.911
CT abdomen 83.91
CT brain 160.31
MRI brain 211.91
Bone scan 140.62
ECG 9.70
Erythrocytes transfusion 183.95
Platelets transfusion  44.15
Terminal care 7450.00
Abbreviations: CT, computed tomography; ECG, electrocardiogram; MRI,
magnetic resonance imaging; X, Rontgen.
Table 2 Cost breakdown for etoposide–cisplatin treatment
and costs of follow-up per state (cost of one cycle)
Unit cost (€) P
1 Cost (€)
Treatment
Chemotherapy 303.94 1.00 303.94
Anemia 654.82 0.25 163.71
Febrile neutropenia 3959.51 0.23 910.69
Thrombocytopenia 25.38 0.15 3.80
Nausea/vomiting 69.73 0.13 9.06
Total treatment costs per cycle 1391.20
Follow-up per state
• Response 101.62
• Stable disease 101.62
• Progressive disease 684.37
• Terminal  7450.00
Note: 
1P = percentage of patients suffering symptoms of toxicity.Therapeutics and Clinical Risk Management 2006:2(3) 320
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Results
After reviewing the literature and based on expert opinion,
it was concluded that a three-steps model would be
appropriate (Carney 1996; ASCO 1997; Pujol et al 2001;
Banerjee et al 2002). We divided the cycles into 3 categories:
cycles 1–3 (treatment allowing the possibility of a response),
cycles 4–6 (treatment but no possibility of a response), and
subsequent cycles. The transition probabilities for each
category are given in Table 3.
For the alternative arms, we assumed that the probability
of a response after the first treatment cycle was 0.30 or 0.35,
with a corresponding decrease in the probability of
progressive disease (0.17 and 0.12 respectively).
Percentage survival at 6 months, 1 and 2 years were
76.3%, 33.4%, and 4.4% respectively in the etoposide–
cisplatin arm (see Table 4). Survival was higher under the
alternative scenarios. More patients remained in the response
state in the alternative arms than in the etoposide–cisplatin
arm.
An increased probability of response leads to a somewhat
improved survival. The gain in life years at 2 years amounted
to approximately 0.02 in favor of alternative treatment A
and 0.044 in favor of alternative B (see Table 5). However,
as these gains are spent in disease stages with a higher quality
of life the gain in QALYs is a little higher.
These results indicated that, under the assumptions of
our model, treatment led to an increased survival of only a
few weeks.
In Table 5, the treatment costs are also presented. We
assumed that the new treatment raises the cost of
chemotherapy from €1391.20 to either €1500 per cycle (a
modest increase) or to €2000 (a substantial increase). The
total costs in the new treatment groups were higher due to
the cost of chemotherapy itself being higher, more patients
received the full course of chemotherapy and (a few) more
patients required follow-up treatment. Most of this
difference occurred during the actual treatment cycles.
Afterwards, these differences did not change substantially.
The incremental cost-effectiveness ratios (∆C/∆E) and
cost-utility ratios (∆C/∆U) are given in Table 6. The ratios
ranged from €22 116 to €81 443. These figures should be
treated cautiously as the magnitude of the denominator was
small, making the estimate unstable.
Sensitivity analysis
A sensitivity analysis was performed to assess the effect of
changes in treatment protocol, response rate, the costs of
the hypothetical drug and using a discount rate.
The most important factor in our model is the treatment
protocol. We compared the results of our model by
comparing the results with a model in which only 4 treatment
cycles were given. This 4-treatment schedule is slightly
cheaper than that used in our model with savings of €144
after 6 months. However, it is also less effective with only
68.2% of patients surviving to that time. By two years, the
difference in effectiveness largely disappears (4.0% survival
vs 4.4%) while the difference in costs increases to €1055.
Increasing the response rate only resulted in a small gain
in life years and QALYs. Furthermore, a higher response
rates implied higher treatment costs. Higher treatment costs
resulted in proportional higher CE and CU ratios.
Table 3 Transition probabilities
From/To Response Stable Progressive Death
disease disease
Cycle 1–3 Response 0.800 0 0.198 0.002
Cycle 4–6 0.800 0 0.195 0.005
Next cycles 0.800 0 0.196 0.004
Cycle 1–3 Stable  0.260 0.522 0.210 0.008
Cycle 4–6 Disease 0 0.805 0.181 0.014
Next cycles 0 0.669 0.314 0.017
Cycle 1–3 Progressive 0 0 0.919 0.081
Cycle 4–6 disease 0 0 0.919 0.081
Next cycles 0 0 0.841 0.159
Table 4 Percentage of patients surviving and in response
Etoposide– Alternative Alternative
cisplatin A B
Response after 1st cycle 26.0 30.0 35.0
Follow-up
6 months Survival 76.3 77.9 79.9
Response 16.1 18.5 21.6
1 year Survival 33.4 34.8 36.6
Response 4.2 4.9 5.7
2 years Survival 4.4 4.6 5.0
Response 0.2 0.3 0.3Therapeutics and Clinical Risk Management 2006:2(3) 321
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Discounting with a rate of 4% results in CE rates varying
from €31 097 to €50 075 and CU rates varying from €30 778
to €36 211. Treatment with etoposide–cisplatin still remained
dominant.
Discussion
There is a rapid growth in health economic literature. Within
oncology, studies in lung cancer are relatively under-
represented, despite the fact that lung cancer is the leading
cause of death (Dranitsaris et al 1998; Goodwin and
Shepherd 1998). Furthermore, lung cancer is accountable
as a major source of morbidity, mortality, and healthcare
costs. It is estimated that lung cancer is responsible for 20%
of all cancer care costs and concerns exists that this spending
is associated with limited benefits (Dranitsaris et al 1998).
It can be seen that under the assumptions of our model,
the future treatment costs of SCLC will increase. As baseline
treatment we considered etoposide–cisplatin therapy. Two-
year costs amounted to approximately €16 038. Considering
an alternative treatment being more effective but also more
costly, the costs increase to approximately €18 171, an
increase of around 12%. The number of life years gained
was very small, only 0.0441 years, around 16 days. The
number of QALYs gained was slightly higher (0.0443),
indicating that the patient will spend more time in a higher
quality of life state. However, even if there is a substantial
rise in the rate of response, the patient can expect only a
relatively small degree of benefit. In this study, we have
concentrated on objective response as a measure of efficacy.
Many physicians feel that this is not a particularly
appropriate measure of this aspect, preferring to choose
survival (Dranitsaris et al 1998). Since new treatment
modalities extends survival by a relatively small amount
compared with the existing treatment, symptom relief and
quality of life should also be considered as appropriate
measures of outcome in an economic model. Another remark
is that we did not include the use of second line
chemotherapy with a possible impact on survival. Further
research should include these possible treatments. However,
the impact on the incremental cost-effectiveness ratio
(ICERs) are expected to be small, as both treatment strategies
will incorporate these second line therapies.
The actual costs of the agents involved in chemotherapy
constitute only a relatively small portion of the total cost of
care of a patient. One important cost driver is hospital
Table 5 Total cumulative life years and quality-adjusted life years (QALYs) per patient
Follow-up
Response
after first
cycle Outcome 6 months 1 year 2 years
Etoposide–cisplatin 0.26 Life years 0.4793 0.7055 0.8360
QALYs 0.3202 0.4564 0.5319
Alternative A 0.30 Life years 0.4844 0.7183 0.8556
QALYs 0.3297 0.4718 0.5516
Alternative B 0.35 Life years 0.4907 0.7343 0.8801
QALYs 0.3415 0.4910 0.5762
Cost of treatment
cycle 6  months 1 year 2 years
Etoposide–cisplatin 0.26 1391 7511 13151 16038
Alternative A 0.30  1500 7946 13633 16644
0.30 2000 8105 13851 17017
Alternative B 0.35 1500 8939 14623 17633
0.35 2000 9259 15006 18171
Table 6 Incremental cost-effectiveness (CE) and cost-utility
(CU) ratios for new treatment alternatives after two years (€)
Response Cost Incremental  Incremental
CE ratio CU ratio 
Alternative A 0.30 1500 30 949 30 822
2000 22 208 22 116
Alternative B 0.35 1500 81 443 81 108
2000 48 930 48 191Therapeutics and Clinical Risk Management 2006:2(3) 322
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admission. In future, some modalities may be administered
on an outpatient basis, leading to a significant decrease in
costs.
Some physicians may feel that the increased costs
associated with new treatments especially associated with
chemotherapy for advanced SCLC outweigh the limited
survival benefits. However, patients also experience
subjective improvement in symptoms such as pain,
coughing, dyspnea, and hemoptysis. Physicians may
consider that such treatments have an important role to play
in palliative care far beyond considerations of cost.
Models have a number of strengths and weaknesses.
Among the latter is that the accuracy of the model is
dependent on the accuracy of the assumptions made
within the model. Economic models attempt to reflect
reality (current clinical practice) but are by definition
merely a reflection. Further, it is often difficult to gain
all necessary data from one source: in this study, we
derived data on the disease progress from a literature
review while the cost data is based on Dutch sources. On
the other hand, such models are easily adaptable, can
easily incorporate multiple end points, can be extended
to reflect actual clinical practice (as opposed to
randomized clinical trials). While in no way being a
replacement for a randomized clinical trial, they can be
used to aid decision making in the face of clinical and
technological development.
New drugs should have at least a significant
improvement on survival and/or progression-free
survival, and/or be substantially better tolerated when
efficacy is the same. Cost-effectiveness analyses intend
to support decision-making. They can provide essential
information on the costs and benefits of drugs and
consequently on the optimal policy mix, thereby
supporting decisions on the adoption and utilization of
new drugs. As more economic evaluations have been
performed, it becomes possible to make comparisons
between healthcare interventions in terms of their relative
CE, in cost per life year gained, or cost per QALY gained.
CE ratios varied exceptionally. Considering the height
of the ratios of applying new drugs and often little impact
on survival, it is clear that the rationale of administering
new treatment modalities are not simply based on
economic reasons.
According to a recently conducted Dutch study
investigating the relationship between disease severity and
willingness to pay, the maximum acceptable cost per QALY
for patients with non-Hodgkin’s lymphoma would be
€45 378 (Poley et al 2003; Uyl-de Groot and Giaccone
2005). It seems that NICE applies an acceptable cost per
QALY gained between €25 600 and €43 800 (Devlin and
Parkin 2004).
The height of the acceptability of a CE ratio should
also depend on other factors such as available alternatives
and severity of the disease. In general, this implies that
in cancer, higher ratios should be accepted. In our opinion
the threshold of the ICER should be around the Dutch
findings for non-Hodgkin’s lymphoma and the NICE
thresholds. For patients with small cell lung cancer, the
thresholds should probably be around €45 000 and
€50 000 per QALY gained on the base of disease severity.
Other factors such as incidence and prevalence of disease
also will have an impact on the decision whether or not
to reimburse new drugs. The higher the number of
patients who need the new drug, the higher the budget
impact will be. We strongly recommend to the authorities
to be more willing to reimburse new cancer drugs, to the
pharmaceutical companies to be more prudent with their
price setting and to hospital management to allow doctors
to use these new drugs.
Conclusion
SCLC is an illness with a poor prognosis using substantial
healthcare resources to optimise patient survival and overall
quality of life. New treatment modalities with better outcome
and favourable cost-effective profiles can hopefully be
developed.
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